584 related articles for article (PubMed ID: 26828965)
1. Molecularly targeted therapy in acute myeloid leukemia.
Gill H; Leung AY; Kwong YL
Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
Naqvi K; Konopleva M; Ravandi F
Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
Bose P; Vachhani P; Cortes JE
Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
[TBL] [Abstract][Full Text] [Related]
4. New strategies for relapsed acute myeloid leukemia: fertile ground for translational research.
Dinner SN; Giles FJ; Altman JK
Curr Opin Hematol; 2014 Mar; 21(2):79-86. PubMed ID: 24419335
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia: advancing clinical trials and promising therapeutics.
Daver N; Cortes J; Kantarjian H; Ravandi F
Expert Rev Hematol; 2016 May; 9(5):433-45. PubMed ID: 26910051
[TBL] [Abstract][Full Text] [Related]
6. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?
Falini B; Gionfriddo I; Cecchetti F; Ballanti S; Pettirossi V; Martelli MP
Blood Rev; 2011 Nov; 25(6):247-54. PubMed ID: 21724308
[TBL] [Abstract][Full Text] [Related]
7. Updates on DNA methylation modifiers in acute myeloid leukemia.
Contieri B; Duarte BKL; Lazarini M
Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
[TBL] [Abstract][Full Text] [Related]
8. Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
Fernandez S; Desplat V; Villacreces A; Guitart AV; Milpied N; Pigneux A; Vigon I; Pasquet JM; Dumas PY
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336846
[TBL] [Abstract][Full Text] [Related]
9. Advances in targeted therapy for acute myeloid leukaemia.
Kayser S; Levis MJ
Br J Haematol; 2018 Feb; 180(4):484-500. PubMed ID: 29193012
[TBL] [Abstract][Full Text] [Related]
10. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents.
Tallman MS
Hematology Am Soc Hematol Educ Program; 2005; ():143-50. PubMed ID: 16304372
[TBL] [Abstract][Full Text] [Related]
11. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.
Birendra KC; DiNardo CD
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):460-5. PubMed ID: 27245312
[TBL] [Abstract][Full Text] [Related]
12. Precision therapy for acute myeloid leukemia.
Yang X; Wang J
J Hematol Oncol; 2018 Jan; 11(1):3. PubMed ID: 29301553
[TBL] [Abstract][Full Text] [Related]
13. New agents for the treatment of acute myeloid leukemia.
Tallman MS
Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukaemia genomics.
Medinger M; Passweg JR
Br J Haematol; 2017 Nov; 179(4):530-542. PubMed ID: 28653397
[TBL] [Abstract][Full Text] [Related]
15. Panobinostat for the treatment of acute myelogenous leukemia.
Morabito F; Voso MT; Hohaus S; Gentile M; Vigna E; Recchia AG; Iovino L; Benedetti E; Lo-Coco F; Galimberti S
Expert Opin Investig Drugs; 2016 Sep; 25(9):1117-31. PubMed ID: 27485472
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy of acute myeloid leukemia in 2012: towards individualized therapy.
Foran JM
Hematology; 2012 Apr; 17 Suppl 1():S137-40. PubMed ID: 22507802
[TBL] [Abstract][Full Text] [Related]
17. Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia.
Newcombe AA; Gibson BES; Keeshan K
Exp Hematol; 2018 Jul; 63():1-11. PubMed ID: 29608923
[TBL] [Abstract][Full Text] [Related]
18. Novel strategies for relapsed and refractory acute myeloid leukemia.
Mato AR; Morgans A; Luger SM
Curr Opin Hematol; 2008 Mar; 15(2):108-14. PubMed ID: 18300756
[TBL] [Abstract][Full Text] [Related]
19. When the good go bad: Mutant NPM1 in acute myeloid leukemia.
Kunchala P; Kuravi S; Jensen R; McGuirk J; Balusu R
Blood Rev; 2018 May; 32(3):167-183. PubMed ID: 29157973
[TBL] [Abstract][Full Text] [Related]
20. Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets.
Reikvam H; Hoang TT; Bruserud Ø
Expert Rev Hematol; 2015 Jun; 8(3):315-27. PubMed ID: 25901742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]